Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 61

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 61
---
 2025                  
 (Unaudited)           
 Nine                  
 Months Ended June 30, 
 2025                  | (702,033 
  376,312 
   17,914 
  103,714 
  (82,274 
   47,562 
      808 
  109,331 
  (94,920 
 (223,586 
        - 
        - 
        - 
  224,631 
  224,631 
    1,045 
      716 
    1,761 
        - 
        - | ) 
 ) 
 ) 
 ) |     | 2024 
 2024 | (397,507 
 261      
 13,045   
 2,324    
 (67,148  
 (2,300   
 (258     
 17,383   
 (110,047 
 (544,247 
 (10,000  
 (40,502  
 535,560  
 -        
 485,058  
 (59,189  
 121,037  
 61,848   
 -        
 -        | ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) |
|:------------------------------------------------------------------------|:----|:----------------------|---------:|:--|:----|:-----|:---------|:--|
| Common                                                                  
 shares issued for note payable                                          |     | $                     |   20,000 |   |     | $    | -        |   |
| Conversion                                                              
 of notes payable to convertible debt                                    |     | $                     |  232,111 |   |     | $    | -        |   |

<div align='center'>The accompanying notes are an integral part of the consolidated financial statements.</div>

| 50 |

<div align='center'>REGEN BIOPHARMA, INC.

Notes to Condensed Consolidated Financial Statements

As of June 30, 2025</div>

1. ORGANIZATION

The Company was organized April 24, 2012 under the laws of the State of Nevada.

The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.

The Company is currently engaged in actively identifying small molecules that inhibit or express NR